absenteeism. [6] [7] [8] A large European study found that younger children
show HRQoL impairments in the dimensions "family" and "treatment," while older children reported higher impairments in social dimensions "perceived support" and "friends," 9 whereas caregivers experienced emotional strain and burden on their schedule providing treatment or managing school and work absences. 10 Extending treatment periods and reduced bleeding rates by maintaining high trough levels may improve HRQoL of patients and their caregivers. 11 This may be achieved with an extended half-life recombinant FIX (rFIX) concentrate. rIX-FP (IDELVION ® ) is a recombinant fusion protein linking rFIX with recombinant albumin, that has a half-life approximately fivefold longer than conventional rFIX. 12 It was demonstrated that a single dose of 50 IU/kg rIX-FP maintained FIX activity above 5 IU/dL after 10 days and above 2 IU/dL after 14 days in paediatric patients. 12 In a phase 3 paediatric study of the PROLONG9-FP clinical programme, rIX-FP prophylaxis resulted in low bleeding rates; with 7-day dosing, the median annualized bleeding rate (ABR) was 3.12, the annualized spontaneous bleeding rate (AsBR) was 0 and patients had an annualized joint bleeding rate (AJBR) of 0.99. 12 These low bleeding rates are consistent with the high trough levels (mean FIX activity of ~14%) that were achieved.
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Here we report the impact of rIX-FP prophylaxis on HRQoL in paediatric patients below the age of 12 years and treatment satisfaction amongst their caregivers.
| MATERIAL S AND ME THODS

| Participants and study design
This was a prospective, non-randomized, international, open-label phase 3 study. Male patients aged 0-11 years with severe or moderate haemophilia B (FIX activity ≤2 IU/dL) who had previously received FIX products (for >150 exposure days [EDs] for patients 6-11 years old, and >50 EDs for patients <6 years old), with no personal or family history of inhibitors were eligible for enrolment. Patients were assigned a dose of 35-50 IU/ kg rIX-FP for weekly prophylaxis, at the investigator's discretion.
The study was approved by the institutional review board/ethics committee at each participating centre, registered at clinicaltrials.gov (NCT01662531), and performed in accordance with good clinical practice, the Declaration of Helsinki and local regulatory requirements. Written informed consent was obtained from the parent/guardian of the patient and informed assent from the patient.
Consent could be withdrawn at any time. The study design and results were published previously. is based on the direct report of the patient about the status of his health condition without interpretation by a clinician or another person, an ObsRO is based on an observation by someone other than the patient or a health professional who observes the patient in daily life and reports on a specific aspect of the patient's health.
Study subjects who were at least 4 years of age were asked to answer the age group-specific self-report version of the haemophiliaspecific HRQoL questionnaire (Haemo-QoL
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) at baseline and at their end-of-study (EOS) visit, at least 12 months later. The Haemo-QoL is an instrument designed to assess the HRQoL of children with haemophilia.
It covers 8-12 domains depending on the age group ("physical health,"
"feeling," "view of yourself," "family," "friends," "perceived support," "other people," "sports and school," "dealing with haemophilia," "treatment," "future" and "relationships"). The version for children aged 4-7 (I) consists of 21 items, the version for children aged 8-12 (II) contains 64 items. Answer categories are based on a 3-point Likert scale for age group I and on a 5-point Likert scale for age group II ranging from "never"
to "always." Some items which were positively formulated had to be inversely recoded and scores were transformed ranging from 0 to 100 with decreasing scores indicating improvements in HRQoL. Missing values were not imputed. Domain scores were calculated when at least 75%
of the items of that domain had been answered, if there were more than 25% missing items the domain and/or the total score were not calculated.
The parent/caregivers of all study subjects were asked to complete the observer-reported haemophilia-specific treatment satisfaction questionnaire (Hemo-Sat P
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) at baseline and at EOS. The
Hemo-Sat P covers 6 domains ("ease & convenience," "efficacy," "burden," "specialist/nurse," "centre/hospital," "general satisfaction") and ranging from "totally agree" to "totally disagree." Some items had to be recoded and scores were transformed ranging from 0 to 100 with decreasing scores indicating improvements in treatment satisfaction.
Socio-demographic data and physical activity level were documented at baseline and throughout the study using single questions asked by the investigator to the caregiver/child on: number of days missed from school due to haemophilia (for school-age children), number of days the caregiver(s) missed from work due to the need of caring for the subject, the number of important life activities missed due to haemophilia for both subject and caregiver(s) and subject's overall activity level (sedentary/moderately active/vigorous).
| Clinical data
Clinical data on bleeding rates, target joints, treatment modality, infusion frequency and adverse events were collected via electronic case report forms. Data on bleeding events and dosing were collected using an e-diary.
| Statistical analysis
Socio-demographic and clinical data for paediatric subjects are reported. Categorical variables are summarized using counts and percentages, while continuous variables are summarized by their means ± SD. Differences over time are reported as Δ means ± SD.
The magnitude of minimal important differences (MID) on a group level, defined by Guyatt as "smallest difference in score in the domain of interest that patients perceive as important and that would lead the clinician to consider a change in the patient's management'', 17 can be determined by distribution-based and anchorbased approaches. 18, 19 In the present study, the MID from baseline to EOS was determined using a distribution-based approach apply- By contrast, responder definitions (RDs) are defined as relevant thresholds identifying meaningful individual change over time. 18 In this paper, RDs of HRQoL and treatment satisfaction were subjectlevel improvements evaluated as the percentage of subjects who showed a decrease in mean values from baseline to EOS greater than a half of the standard deviation at baseline. 19, 21 No statistical testing was performed due to lack of power by cause of small sample sizes. All statistical analyses were performed 
| RE SULTS
| Patient characteristics and clinical outcomes
Twenty-seven patients were enrolled from 17 centres in 10 countries Patients' baseline demographic data for the entire cohort are shown in Table 1 . Clinical study results have already been published.
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Patients who reported HRQoL data at both baseline and EOS (n = 17) had a reduction in mean ABR and AsBR from baseline to EOS. Two patients in this cohort had target joints at baseline, both patients experienced resolution of their target joints by EOS (Table 2 ).
| Patient-reported outcomes (PROs) and observer-reported outcomes (ObsRO)
Health-related quality of life data were available for 21 patients who had completed the Haemo-QoL questionnaire at any time; one patient only had EOS data and three patients had only baseline data.
A complete data set including clinical data and HRQoL data at both baseline and EOS is available for 17 patients (Figure 1 ). The study duration for patients reporting HRQoL data at both baseline and EOS (n = 17) was a mean ± SD 451.7 ± 75.82 days.
At EOS, these patients reported improvements in key socio-demographic characteristics, as shown in Table 2 maintained or improved their physical activity levels compared to baseline.
| Impact of rIX-FP prophylaxis on patients' HRQoL (Haemo-QoL)
Patients in age group I had a good HRQoL (n = 12) at baseline, with the highest impairments in the domains "family," "physical health"
and "treatment" of the Haemo-QoL. Patients in age group II (n = 8)
reported the highest impairments at baseline in social domains, namely "support," "friends" and "family" (Table 3) .
At EOS, MIDs between baseline and EOS in age group I (n = 10)
were represented by medium effect sizes observed as improvement in "physical health" and decline in "treatment" domain scores at EOS (Figure 2 ).
TA B L E 1 Baseline demographics and patient characteristics for the entire study cohort
Baseline N = 27
Age in years, mean ± SD 5.9 ± 2.93
Race, n (%) BMI, body mass index; SD, standard deviation. a Categories were calculated based on the BMI-for-age percentiles 34 ; for 3 patients the BMI category could not be calculated since they were younger than 2 y old. b Percentages are based on the number of patients who received prophylaxis prior to study entry.
In age group II (n = 7) the MIDs were represented by medium to large effect sizes for most of the Haemo-QoL domains. The largest improvements in HRQoL were seen in the "total score" and the Haemo-QoL domains "dealing,'" "family" and "physical health"
( Figure 3 ).
Mean changes over time in all Haemo-QoL scores, responder thresholds and percentage of responders are presented in Table 3 .
In age group I, 60% of patients were responders in the domain "physical health." The lowest number of responders was seen in the domain "treatment" (11.1%). In age group II, 71.4% of patients were responders in "total score" based on the responder definition, whilst >50% of patients were responders in the domains "family," "sport and school," "dealing" and "other". The lowest number of responders were seen in the domains "treatment" and "friends" (14.3%).
| Impact of rIX-FP prophylaxis on caregiver treatment satisfaction
The Hemo-Sat P questionnaire was completed by the caregivers of 23 patients (including caregivers of children younger than 2 years).
The mean study duration from baseline to EOS for caregivers was 425.7 ± 81.19 days. Caregivers showed high treatment satisfaction at baseline in the Hemo-Sat P total score (14.5 ± 11.21).
For caregivers, MIDs were represented by small effect sizes (Cohen's d) for most of the Hemo-Sat P domains (Figure 4 ). The largest improvement was seen in the domain "burden" with small improvements seen in "general satisfaction," and a decline in the "specialist" domain. At subject level, 34.8% of caregivers were responders, based on the responder definition, with an improvement in the total Hemo-Sat P score ( Table 4 ). The highest number of responders was seen in the domain "ease and convenience" with 43.5% of caregivers above the responder threshold. The lowest number of responders was seen in the "centre" domain (13.0%). TA 
| D ISCUSS I ON
B L E 2 Clinical outcomes and socio-demographic data for patients with HRQoL data at baseline and end-of-study (EOS)
F I G U R E 1 Flow chart study population
Both age groups saw a large improvement in the domain "physical health." In age group I, the mean change in score from baseline to EOS was (Δ) = −11. 3 ± 19.94, with 60% of patients being responders.
In age group II the change in mean score was Δ = −11.7 ± 23.30, with 42.9% of patients being responders. This substantial improvement in "physical health" may be due to the reduction in bleeds from which was similar to our study (median = 26.4). They found a median change in the Haemo-QoL "total score" of −1.6, implying a trend towards improvement. 24 The median improvement in our study with rIX-FP (6/7). 24 Both N9-GP and rIX-FP treatment led to improvements in HRQoL, however, due to the small sample sizes in both studies no further comparisons can be made. In the B-LONG study, 73 adult haemophilia B patients were treated with rFIXFc (Alprolix ® ) and were followed up for 26 weeks.
TA B L E 3 Patient level responders according to the Haemo-QoL
HRQoL was assessed using the Haem-A-QoL and HRQoL Responder
Definitions for key domains of the Haem-A-Q oL were calculated, as in our study. Prophylaxis with rFIXFc led to an improvement in HRQoL with a relatively high number of responders. Greater improvements were seen in patients switching from on-demand to prophylactic treatment. 27 Although this study is in adults, and not directly comparable, it will be interesting to see if the improvement in HRQoL seen with rIX-FP is maintained in adult and adolescent patients to a similar or greater degree than seen with other long-acting factors.
When we compare haemophilia A and B, we can see that adult
patients have similar bleeding rates 9 and HRQoL. 27 Similar to results in our study, paediatric patients with haemophilia A that switched to BAX 855, a glycopegylated rFVIII, saw an improvement in HRQoL in all domains of the Paediatric Quality of Life Inventory. However, this did not reach significance in the youngest cohort. 28 No other longacting FVIII has published quality-of-life data for paediatric patients.
As stated previously, the finding that the youngest patients do not see a benefit in HRQoL seems consistent, and bears further study. A limitation of our analysis is that it was performed on a small number of patients, due to the small pool of paediatric patients with haemophilia B. This is a common challenge in rare bleeding disorders.
The use of responder definitions and MID improves the identifica- 
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